PLx Pharma Winddown Corp. financial data

Industry
Pharmaceutical Preparations
Location
9 Fishers Lane, Suite E, Sparta, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
PLx Pharma Inc. (to 5/2/2023), Dipexium Pharmaceuticals, Inc. (to 4/20/2017), Dipexium Pharmaceuticals, LLC (to 3/13/2014)
Latest financial report
10-Q - Q3 2022 - Nov 10, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 501 % -72.2%
Quick Ratio 33 %
Debt-to-equity 71.2 % -33.7%
Return On Equity -125 % +43.3%
Return On Assets -51.2 % +35.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.1M shares +5.81%
Common Stock, Shares, Outstanding 29.1M shares +6.04%
Common Stock, Value, Issued 29K USD +5.54%
Weighted Average Number of Shares Outstanding, Basic 28.6M shares +6.29%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 4.34M USD -62.7%
Research and Development Expense 2.52M USD -46.6%
Operating Income (Loss) -64.4M USD -173%
Nonoperating Income (Expense) 36.8M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.6M USD +52.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.6M USD +52.2%
Earnings Per Share, Basic -0.3 USD/shares +62.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.8M USD -68.7%
Accounts Receivable, after Allowance for Credit Loss, Current 139K USD -95.7%
Inventory, Net 3.18M USD +45.1%
Assets, Current 30.2M USD -65.9%
Property, Plant and Equipment, Net 768K USD -13.6%
Operating Lease, Right-of-Use Asset 204K USD -18.3%
Goodwill 2.06M USD 0%
Other Assets, Noncurrent 174K USD
Assets 33.2M USD -63.8%
Liabilities, Current 6.31M USD -14.8%
Other Liabilities, Noncurrent 46K USD -72.2%
Liabilities 7.02M USD -84.4%
Retained Earnings (Accumulated Deficit) -179M USD -18.2%
Stockholders' Equity Attributable to Parent 10.2M USD -67%
Liabilities and Equity 33.2M USD -63.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.9M USD -295%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 29.1M shares +6.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.9M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 52.5M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Operating Lease, Liability 172M USD +61465%
Lessee, Operating Lease, Liability, to be Paid 184M USD +59222%
Lessee, Operating Lease, Liability, to be Paid, Year Two 31.8M USD +27872%
Lessee, Operating Lease, Liability, to be Paid, Year One 118M USD +89075%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.9M USD +38808%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 930K shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 30K USD +11.1%
Share-based Payment Arrangement, Expense 4.3M USD +57.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%